CoVLP information

CoVLP
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Trade names	Covifenz
Routes of; administration	Intramuscular
Legal status
Legal status	CA: ℞-only;
Identifiers
DrugBank	DB15852;

CoVLP (brand name Covifenz) was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.^[6]

It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.^[7]^[8]^[9]^[10]

The Medicago method to manufacture CoVLP was a "molecular farming" technology regarded as rapid, low-cost, and safe.^[8]^[11] It was proposed specifically for production of COVID-19 vaccines.^[12]^[13]

In February 2022, Health Canada authorized use of CoVLP for preventing COVID-19 infection in adults 18 to 64 years old.^[3] The authorization stated there was an efficacy rate of 71% after two vaccinations against symptoms of COVID-19 disease and 100% efficacy against severe COVID-19 infections.^[3]

^ "Product monograph for Covifenz" (PDF). Medicago, Inc. 24 February 2022.
^ "Medicago Covifenz COVID-19 vaccine". Health Canada. 24 February 2022. Retrieved 29 May 2022.
^ ^a ^b ^c "Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age" (Press release). Health Canada. 24 February 2022. Retrieved 24 February 2022.
^ "Summary Basis of Decision (SBD) for Covifenz". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein)". Health Canada. 24 February 2022. Retrieved 31 May 2022.
^ Cite error: The named reference lavery was invoked but never defined (see the help page).
^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
^ ^a ^b LeBlanc Z, Waterhouse P, Bally J (December 2020). "Plant-Based Vaccines: The Way Ahead?". Viruses. 13 (1): 5. doi:10.3390/v13010005. PMC 7822169. PMID 33375155.
^ St Philip E, Favaro A, MacLeod M (14 July 2020). "The hunt for a vaccine: Canadian company begins human testing of COVID-19 candidate". CTV News. Retrieved 14 July 2020.
^ Chander V (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Retrieved 14 July 2020.
^ Fischer R, Buyel JF (2020). "Molecular farming - The slope of enlightenment". Biotechnology Advances. 40: 107519. doi:10.1016/j.biotechadv.2020.107519. PMID 31954848. S2CID 210830170.
^ Dhama K, Natesan S, Iqbal Yatoo M, Patel SK, Tiwari R, Saxena SK, Harapan H (December 2020). "Plant-based vaccines and antibodies to combat COVID-19: current status and prospects". Human Vaccines & Immunotherapeutics. 16 (12): 2913–2920. doi:10.1080/21645515.2020.1842034. PMC 7754927. PMID 33270484.
^ Balfour H (15 April 2020). "Plant bio-factories contributing to the COVID-19 fight". Drug Target Review. Retrieved 30 January 2021.

[1] "Product monograph for Covifenz" (PDF). Medicago, Inc. 24 February 2022.

[2] "Medicago Covifenz COVID-19 vaccine". Health Canada. 24 February 2022. Retrieved 29 May 2022.

[hc-3] "Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age" (Press release). Health Canada. 24 February 2022. Retrieved 24 February 2022.

[4] "Summary Basis of Decision (SBD) for Covifenz". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[5] "Covifenz (virus-like particles (VLP) of SARS-CoV-2 spike protein)". Health Canada. 24 February 2022. Retrieved 31 May 2022.

[lavery-6] Cite error: The named reference lavery was invoked but never defined (see the help page).

[Hotez-7] Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.

[leblanc-8] LeBlanc Z, Waterhouse P, Bally J (December 2020). "Plant-Based Vaccines: The Way Ahead?". Viruses. 13 (1): 5. doi:10.3390/v13010005. PMC 7822169. PMID 33375155.

[ctv-medicago-9] St Philip E, Favaro A, MacLeod M (14 July 2020). "The hunt for a vaccine: Canadian company begins human testing of COVID-19 candidate". CTV News. Retrieved 14 July 2020.

[np-medicago-10] Chander V (14 July 2020). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post. Reuters. Retrieved 14 July 2020.

[fischer-11] Fischer R, Buyel JF (2020). "Molecular farming - The slope of enlightenment". Biotechnology Advances. 40: 107519. doi:10.1016/j.biotechadv.2020.107519. PMID 31954848. S2CID 210830170.

[dhama-12] Dhama K, Natesan S, Iqbal Yatoo M, Patel SK, Tiwari R, Saxena SK, Harapan H (December 2020). "Plant-based vaccines and antibodies to combat COVID-19: current status and prospects". Human Vaccines & Immunotherapeutics. 16 (12): 2913–2920. doi:10.1080/21645515.2020.1842034. PMC 7754927. PMID 33270484.

[balfour-13] Balfour H (15 April 2020). "Plant bio-factories contributing to the COVID-19 fight". Drug Target Review. Retrieved 30 January 2021.

CoVLP information

and 25 Related for: CoVLP information

CoVLP

Nicotiana benthamiana

Bacteriophage AP205

Pakse International Airport

Pseudoviridae

List of compositions by Johann Sebastian Bach

Ian Frazer

List of abbreviations in oil and gas exploration and production

Polydnaviriformidae

Helsinki

Mycovirus

Laryngoscopy

Absolutely Free

Psittacine beak and feather disease

2023 TCR Brazil Touring Car Championship

Gardasil

Virus nanotechnology

Chikungunya vaccine

LaserDisc

Human papillomavirus infection

HPV vaccine

Cervarix

Banded iron formation

Parvovirus B19

2021 in science

COVID-19 pandemic
Part of a series on the
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023 2024
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e